Page 53 - Oncology Coder News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncology coder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncology Coder Today - Breaking & Trending Today

Sacituzumab govitecan shows survival benefit in endocrine-resistant hormone-positive metastatic breast cancer

1. Median overall survival increased by 3.2 months in the sacituzumab govitecan group compared to chemotherapy. 2. One fatal treatment-related adverse event was reported in the sacituzumab group. Evidence Rating Level: 1 (Excellent) Study Rundown: In phase 3 of the TROPiCS-02 trial, sacituzumab govitecan demonstrated significant survival benefit versus chemotherapy among patients with hormone-receptor-positive (HR+) ....

United States , Sacituzumab Govitecan , Rating Level , Metastatic Triple Negative Breast , Between May , North America , Breast Cancer , Hormone Receptor Positive Breast Cancer , Metastatic Breast Cancer , Chronic Disease ,

Is the EU falling behind in transforming lung cancer care?

Despite its pivotal role in the EU’s Beating Cancer Plan, patients have yet to fully benefit from next-generation sequencing. A groundbreaking report highlights what we can do to change this. ....

Europe Luce Atlas , Takeda Pharmaceuticals International , Office Of Health Economics , European Federation Of Pharmaceutical Industries , Precision Medicine Working Group , European Commission , European Society For Medical Oncology , Cancer Plan , Health Economics , Expanding Uptake , Next Generation Sequencing , Lung Cancer , Lung Cancer Europe , Lung Cancer Treatment , Biomarker Testing , Beating Cancer Plan , Medicine Working , European Society , Medical Oncology , European Federation , Pharmaceutical Industries , Aid And Development , Cells And Tissues , Certification And Standards , Health Care , Health Systems ,

Rituximab Reference vs Biosimilar Utilization for Oncology vs Nononcology Indications

Reporting on the real-world utilization of reference rituximab and its biosimilars can help show prescribing habits and reveal cost-saving opportunities. ....

United States , Rheinland Pfalz , Rituximab Rituxan , Bonniea Labdi , J Health Syst Pharm , Long Island University Pharmacy , Margolis Center , Duke University , Association For Accessible Medicines , Craneware Group , International Statistical Classification Of Diseases , Life Sciences , Trisus Medication Compare , International Statistical Classification , Tenth Revision , Appendix Table , Quarterly Utilization , Biosimilar Product , Deerfield Beach , Health Policy , Updated April , Manag Care Spec ,

Dr Edward Arrowsmith: Trust and Compromise Are Essential in Building Oncology Clinical Care Pathways

Edward "Ted" Arrowsmith, MD, MPH, medical director for pathways at OneOncology and managing partner at Tennessee Oncology, highlights the need for trust between payers and providers, as well as finding balance in building consistent clinical pathways while prioritizing specific practice needs. ....

United States , Edward Ted Arrowsmith , Tennessee Oncology , Clinical Pathways Have Burnout , Patient Centered Oncology Care , Clinical Pathways ,

Dr Amitkumar Mehta: CAR T-Cell and Bispecific Therapy Are Complementary, Not Competitors

Amitkumar Mehta, MD, MBA, University of Alabama at Birmingham, notes the long-term data and potential curative effects of chimeric antigen receptor (CAR) T-cell therapy, while expressing optimism about bispecific therapy with ongoing evolution and the chance of significant patient responses. ....

Amitkumar Mehta , University Of Alabama At Birmingham , Cell Therapy , Cost Consideration , Patient Centered Oncology , Cart Cell Therapy ,